Tumor Response baseline to measured progressive disease (up to 5 years) [clinicaltrials_resource:90657f2d8f937610a3f451b6896a5f61]
Pemetrexed: 900 mg/m2 (700 mg/m2 for patients with prior radiotherapy) intravenous (IV) over 10 minutes every 21 days until disease progression.
clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]
Tumor Response baseline to measured progressive disease (up to 5 years) [clinicaltrials_resource:90657f2d8f937610a3f451b6896a5f61]
Pemetrexed: 900 mg/m2 (700 mg/m2 for patients with prior radiotherapy) intravenous (IV) over 10 minutes every 21 days until disease progression.
Bio2RDF identifier
90657f2d8f937610a3f451b6896a5f61
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:90657f2d8f937610a3f451b6896a5f61
measure [clinicaltrials_vocabulary:measure]
Tumor Response
time frame [clinicaltrials_vocabulary:time-frame]
baseline to measured progressive disease (up to 5 years)
description
Pemetrexed: 900 mg/m2 (700 mg/ ...... ays until disease progression.
identifier
clinicaltrials_resource:90657f2d8f937610a3f451b6896a5f61
title
Tumor Response baseline to measured progressive disease (up to 5 years)
@en
type
label
Tumor Response baseline to mea ...... 57f2d8f937610a3f451b6896a5f61]
@en